Q4 and full-year 2024 revenues surged to $1.1B and $3.8B respectively. Check out why I rate ONC stock as a Buy.

Research reveals promising advancements of Ce6-GFFY in colorectal cancer treatment. Colorectal cancer (CRC) is a highly malignant disease that readily metastasizes to vital organs. Many strategies ...

Creative Bioarray Enhances Cancer Research with Innovative Drug Efficacy Testing Services NEW YORK CITY, NY, UNITED STATES, March 3, 2025 /EIN ...

The primary target is TNNI3, a gene linked to HCM. The study leverages molecular descriptors, IC50 filtering, and visualization techniques to identify potential drug candidates. A RandomForest ML ...

Control cells were cultured in media, whereas treated cells were treated with the extract for 48 h with their corresponding IC50 concentration. DMSO was used as a negative control. Q1, Q2, Q3, and Q4 ...

Research reveals promising advancements of Ce6-GFFY in colorectal cancer treatment. Colorectal cancer (CRC) is a highly ...

Total Revenue (Q4 2024): $59.9 million, up 33% from $45.1 million in Q4 2023. Total Revenue (Full Year 2024): $235.1 million, up 34% from $175.5 million in 2023. Net Product Sales of LUPKYNIS (Q4 ...

Parkinson’s disease (PD) is one of the most common neurodegenerative diseases in which neuroinflammation plays pivotal roles. An important mechanism of neuroinflammation is the NLRP3 inflammasome ...

School of Materials Science and Engineering, Key Laboratory for Polymeric Composite and Functional Materials of Ministry of Education, Sun Yat-sen University, Guangzhou 510275, China ...